FENC vs LCTX vs RCKT vs NKTR

For growth investors, Fennec Pharmaceuticals Inc.

(FENC) is the stronger pick with 123. 7% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Analysts rate Fennec Pharmaceuticals Inc. (FENC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Fennec Pharmaceuticals Inc.

(FENC) delivered a total return of +11. 8%, compared to -91. 6% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: FENC returned -42. 3% versus RCKT's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Rocket Pharmaceuticals, Inc.

(RCKT) is the lower-risk stock at 1. 21β versus Nektar Therapeutics's 1. 80β — meaning NKTR is approximately 49% more volatile than RCKT relative to the S&P 500. On balance sheet safety, Lineage Cell Therapeutics, Inc. (LCTX) carries a lower debt/equity ratio of 6% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Fennec Pharmaceuticals Inc.

(FENC) is pulling ahead at 123. 7% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Fennec Pharmaceuticals Inc. grew EPS 97. 3% year-over-year, compared to -201. 1% for Lineage Cell Therapeutics, Inc.. Over a 3-year CAGR, LCTX leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Rocket Pharmaceuticals, Inc.

(RCKT) is the more profitable company, earning 0. 0% net margin versus -436. 5% for Lineage Cell Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FENC leads at 5. 4% versus -251. 6% for LCTX. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FENC: 160.

9% to $18. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Rocket Pharmaceuticals, Inc.

(RCKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RCKT: -91. 4%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FENC is a small-cap high-growth stock; LCTX is a small-cap high-growth stock; RCKT is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.